Navigation Links
Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
Date:2/10/2010

JERUSALEM, Israel, February 10 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that its Chief Scientific Officer, Miriam Kidron, Ph.D., was chosen to lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) to take place in Basel, Switzerland on February 11, 2010. Dr. Kidron will present the following abstract in Hall B at 3:15 pm: "Assessment of Oral Insulin Formulations in the Healthy Male Volunteers - Safety and Pharmacodynamic Comparisons".

Based on the conference website, the conference "presents professionals with cutting-edge technologies from entrepreneurs racing to develop effective and advanced devices and systems for the treatment and prevention of diabetes and related illnesses." For more information please visit the conference website at: http://www2.kenes.com/attd/pages/home.aspx.

Oramed is currently conducting a Phase 2B clinical trial in South Africa on its flagship product an oral insulin capsule. Results are expected at the end of the first quarter of 2010.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com.

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oramed, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and Oramed's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to Oramed's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of Oramed to differ materially from those expressed or implied in such forward looking statements. Oramed undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relations Contact:

    Oramed Pharmaceuticals Inc.
    Tara Horn
    USA: +1-646-240-4193
    Int'l: + 972-54-334-318
    Office: + 972-2-566-0001
    Email: tara@oramed.com


SOURCE Oramed Pharmaceuticals Inc.


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
2. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
3. Fibrocell Science, Inc. Names David Pernock Chief Executive Officer
4. Glycos Biotechnologies Appoints Chief Executive Officer
5. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
6. Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer
7. Dendreon Appoints Hans Bishop as Chief Operating Officer
8. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
9. Advanced Cell Technologys Chief Scientific Officer, Robert Lanza, Opening Plenary Speaker at the 3rd International Conference on Cell Therapy
10. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
11. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... recipients of 13 prestigious awards honoring scientists who have made ... in a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
(Date:10/7/2017)... 6, 2017  The 2017 Nobel Prize in ... Jacques Dubochet, Joachim Frank and ... cryo-electron microscopy (cryo-EM) have helped to broaden ... biology community. The winners worked with systems manufactured ... produce highly resolved, three-dimensional images of protein structures ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):